about
Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trialSerum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trialPlasma phospholipid fatty acids and prostate cancer risk in the SELECT trialDietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition StudyCorrelates of serum alpha- and gamma-tocopherol in the Women's Health Initiative.Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis.Low-fat, low-glycemic load diet and gene expression in human prostate epithelium: a feasibility study of using cDNA microarrays to assess the response to dietary intervention in target tissues.How can stages of change be best used in dietary interventions?Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik EskimosDifferential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect.A practical method for collecting food record data in a prospective cohort study of breast cancer survivors.Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.Finasteride reduces the risk of incident clinical benign prostatic hyperplasiaSerum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.Total mortality risk in relation to use of less-common dietary supplementsMen with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.Iron intake, oxidative stress-related genes (MnSOD and MPO) and prostate cancer risk in CARET cohort.Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants.Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohortIntra-individual variation in serum C-reactive protein over 4 years: an implication for epidemiologic studies.Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention TrialSpecialty supplements and prostate cancer risk in the VITamins and Lifestyle (VITAL) cohort.Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.Correlation between selenium concentrations and glutathione peroxidase activity in serum and human prostate tissue.Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention TrialSerum selenium, genetic variation in selenoenzymes, and risk of colorectal cancer: primary analysis from the Women's Health Initiative Observational Study and meta-analysis.Stable nitrogen and carbon isotope ratios indicate traditional and market food intake in an indigenous circumpolar population.First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement.Vitamin A, retinoids and carotenoids as chemopreventive agents for prostate cancer.Genetic variation in GPX1 is associated with GPX1 activity in a comprehensive analysis of genetic variations in selenoenzyme genes and their activity and oxidative stress in humans.The prevalence of stunting is high in HIV-1-exposed uninfected infants in Kenya.Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature.Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins And Lifestyle (VITAL) cohortNutrition and physical activity and chronic disease prevention: research strategies and recommendations.Reliability of serum biomarkers of inflammation from repeated measures in healthy individualsA practical method for collecting 3-day food records in a large cohort.Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
P50
Q24594183-ACA6B048-3310-4C23-9540-C8B0ACF2EE7EQ24627834-88967773-B274-47EF-A2AE-590DA345B5F0Q24633239-7E32F604-3FC6-4ADF-890B-701FD6A72C30Q28279778-EB3AC385-5F46-4B8B-8354-6FA433B4F8A2Q31866717-0EC5B225-8E01-43BD-92EB-08F4E69A9022Q33249011-D691A9A6-864A-4ABA-BE6F-3574550B42DBQ33302399-C98C44B1-6FB5-4988-8868-6A35179FE79DQ33653541-808EEDC7-5A4F-4D60-9171-B0D946677940Q33666208-CADC2AB7-F561-43CC-8986-B5BCE000ECEAQ33714055-F92B1B1B-BBBC-439E-A0C9-780C7995D3D1Q33715224-40C8A44F-B594-4077-9417-1A20D26D4656Q33725858-5266B67D-FC3D-4970-AC1D-5402A8CC4733Q33741548-A8E3E5F6-449D-4AC9-9454-627A14F2DF78Q33762340-CF1AF4EF-156B-4070-AC5A-77A8652BFEC0Q33785724-46F65AC9-2432-4BB7-8105-259CD6B59DF0Q33849348-08FB47E1-0BFD-4867-9918-953F6737FD72Q33882778-C323F78D-EF76-4C6F-96B4-9C81ECD53717Q33986231-FA2475A0-4746-415D-ADCB-95B2CA63D569Q34310309-369CB80C-E5FC-4BB0-9330-633A077A739BQ34422409-162B63A3-655C-4175-A99F-64A6338F6929Q34443714-0A431B6F-56CC-4BB5-968D-9360F288BB76Q34682926-BA7DDFE1-9B81-4152-8C30-6112FB5E15DDQ34748580-C22B399B-F657-46E9-95A0-E7348C17FF03Q34756869-43485EB6-B401-4B2A-BC68-95611DB518A1Q35001509-B1522A4A-EE4F-461F-8993-9BB2AC95D5A3Q35116362-0EF6A10F-E8BC-4C96-BD2F-480889FB89F8Q35194352-FA99461A-C96F-439C-81CF-7F246555B2A6Q35230322-66B789D5-DE49-4644-9324-622ADC384F14Q35316267-B5CF3129-09F1-4348-9F11-96C1D3AC9433Q35611013-47666845-B00D-4A3B-A15F-52CE2F946A1BQ35624772-6C95BF79-4E2E-4F2A-A2B9-2AAD783F3637Q35624821-9A700606-1121-47F6-A5B9-9C52424F7465Q35753199-BCD36D27-546A-474B-941D-BDD285036D97Q35825248-A8B70421-4CC0-445E-84FF-02BD2A27DC30Q35859544-ECB28E66-3691-4984-84A5-74B83516B750Q35869220-3CD867C3-4D12-431C-96BB-2D35DA6BBE96Q35875888-859FF556-A0C1-4FF4-B6C2-2E158A6B038CQ36083671-33D9EF50-BEF2-4F7C-9CCB-4C4C72AE269EQ36160782-AFAF60D4-9B6E-4290-8E22-6AA95A2AFDACQ36306367-32F2A0CB-4F9C-4A56-A2AE-A491E5CA3C39
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alan R. Kristal
@ast
Alan R. Kristal
@en
Alan R. Kristal
@es
Alan R. Kristal
@nl
Alan R. Kristal
@sl
type
label
Alan R. Kristal
@ast
Alan R. Kristal
@en
Alan R. Kristal
@es
Alan R. Kristal
@nl
Alan R. Kristal
@sl
prefLabel
Alan R. Kristal
@ast
Alan R. Kristal
@en
Alan R. Kristal
@es
Alan R. Kristal
@nl
Alan R. Kristal
@sl
P106
P1153
35372493900
P21
P31
P496
0000-0002-7329-1617